Medication info
Hanubi Tablet 100 mg (Sitagliptin Phosphate)

Hanubi Tablet 100 mg (Sitagliptin Phosphate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate›124.08mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Beige, round, biconvex film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 201503214 · Approved 2015.05.27 · Insurance code 647805500

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dosage adjustment is necessary in patients with mild renal impairment (eGFR ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dosage adjustment is necessary in patients with moderate renal impairment (eGFR ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It may be administered alone if blood sugar control is insufficient, or in combination with metformin. Additionally, it can be used as an add-on therapy when existing treatments with sulfonylureas, metformin, thiazolidinediones, or insulin, whether alone or in combination, are not sufficiently effective. This medication aids in improving blood sugar control in conjunction with various treatment methods.

How to take

Adult dose

Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dosage adjustment is necessary in patients with mild renal impairment (eGFR ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dosage adjustment is necessary in patients with moderate renal impairment (eGFR ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication can rarely cause severe allergic reactions, so if skin rash, difficulty breathing, or swelling of the face or neck occurs after taking it, you should immediately stop taking it and consult a doctor. During administration, symptoms of acute pancreatitis such as severe abdominal pain, vomiting, and fever may occur; if these symptoms appear, immediate medical attention should be sought. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should be avoided in case of allergy to this medication or its components. Patients with reduced kidney function should have their dosage adjusted, and regular kidney function tests are important. Hypoglycemic symptoms may occur during treatment, and the risk of hypoglycemia may increase, especially when taken together with other hypoglycemic agents such as insulin or sulfonylureas. If severe joint pain or skin blisters occur, you should notify your doctor immediately and discontinue the medication. Pregnant and nursing women are not recommended to use this medication, and safety for children and adolescents under 18 years old has not been established. Elderly patients may require dosage adjustment and kidney function testing due to potential renal impairment. In cases of overdose, general treatment procedures may be considered, and dialysis may be required based on necessity; therefore, dosage must be strictly adhered to. This medication has little to no significant interactions with various other medications, but it is advisable to consult healthcare professionals when taking certain medications. It is important to consult healthcare professionals immediately if any abnormal symptoms or discomfort arise during administration.

Side effects

  • Severe hypersensitivity reaction
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory tract infection
  • headache
Show 28 more
  • diarrhea
  • abdominal pain
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • increased low-density lipoprotein
  • hyperglycemia

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent air exposure, and it is advisable to keep it at room temperature between 1°C and 30°C. Proper storage will help maintain the medication's efficacy and prevent deterioration.

Appearance and packaging

Appearance

Beige, round, biconvex film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.